Bettzy Stephen

1.8k total citations
56 papers, 978 citations indexed

About

Bettzy Stephen is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Bettzy Stephen has authored 56 papers receiving a total of 978 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 15 papers in Cancer Research and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Bettzy Stephen's work include Cancer Immunotherapy and Biomarkers (21 papers), Cancer Genomics and Diagnostics (8 papers) and Lung Cancer Treatments and Mutations (6 papers). Bettzy Stephen is often cited by papers focused on Cancer Immunotherapy and Biomarkers (21 papers), Cancer Genomics and Diagnostics (8 papers) and Lung Cancer Treatments and Mutations (6 papers). Bettzy Stephen collaborates with scholars based in United States, Netherlands and Türkiye. Bettzy Stephen's co-authors include Aung Naing, Siqing Fu, David S. Hong, Apostolia M. Tsimberidou, Vivek Subbiah, Sarina A. Piha‐Paul, Daniel D. Karp, Jennifer J. Wheler, Razelle Kurzrock and Filip Jankú and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Bettzy Stephen

52 papers receiving 963 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bettzy Stephen United States	16	454	388	270	233	145	56	978
Tyler P. Robin United States	17	608 1.3×	198 0.5×	405 1.5×	272 1.2×	330 2.3×	55	1.3k
Francesca Riva Italy	17	471 1.0×	402 1.0×	423 1.6×	240 1.0×	165 1.1×	32	1.0k
Ciara M. Kelly United States	15	520 1.1×	129 0.3×	498 1.8×	184 0.8×	136 0.9×	64	1.1k
Casey W. Williamson United States	13	376 0.8×	184 0.5×	204 0.8×	146 0.6×	301 2.1×	30	926
Alessia Mennitto Italy	19	549 1.2×	225 0.6×	479 1.8×	212 0.9×	271 1.9×	59	1.0k
Antonio De Leo Italy	17	228 0.5×	155 0.4×	230 0.9×	164 0.7×	191 1.3×	101	869
Guillermo Villacampa Spain	14	587 1.3×	264 0.7×	327 1.2×	66 0.3×	226 1.6×	90	1.1k
Cristian Lolli Italy	19	578 1.3×	331 0.9×	761 2.8×	263 1.1×	274 1.9×	88	1.4k
Thomas J. Semrad United States	15	395 0.9×	162 0.4×	237 0.9×	122 0.5×	257 1.8×	51	890

Countries citing papers authored by Bettzy Stephen

Since Specialization

Citations

This map shows the geographic impact of Bettzy Stephen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bettzy Stephen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bettzy Stephen more than expected).

Fields of papers citing papers by Bettzy Stephen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bettzy Stephen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bettzy Stephen. The network helps show where Bettzy Stephen may publish in the future.

Co-authorship network of co-authors of Bettzy Stephen

This figure shows the co-authorship network connecting the top 25 collaborators of Bettzy Stephen. A scholar is included among the top collaborators of Bettzy Stephen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bettzy Stephen. Bettzy Stephen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stephen, Bettzy, Jeffrey How, Justin T. Moyers, et al.. (2025). Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial. PubMed. 8(2). 143–151. 1 indexed citations

Ahmed, Jibran, Daniel D. Karp, Sarina A. Piha‐Paul, et al.. (2025). A phase 2 basket study of talabostat, a small‐molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers. Cancer. 131(3). e35728–e35728. 3 indexed citations

Hajjar, Joud, Bettzy Stephen, Serdar A. Gurses, et al.. (2025). Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors. ESMO Open. 10(8). 105518–105518. 1 indexed citations

Gouda, Mohamed A., Bettzy Stephen, Yanyan Tian, et al.. (2024). A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma. SHILAP Revista de lepidopterología. 7(4). 247–254. 2 indexed citations

Coleman, Niamh, Bettzy Stephen, Siqing Fu, et al.. (2024). Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors. Cancer Medicine. 13(3). e6877–e6877. 5 indexed citations

Hein, Kyaw Zaw, Bettzy Stephen, & Siqing Fu. (2023). Therapeutic Role of Synthetic Lethality in ARID1A -Deficient Malignancies. SHILAP Revista de lepidopterología. 7(1). 41–52. 3 indexed citations

Altan, Mehmet, Denái R. Milton, Bülent Yılmaz, et al.. (2023). Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non–small cell lung cancer. Cancer. 129(17). 2685–2693. 6 indexed citations

Ahmed, Jibran, Bettzy Stephen, Sarina A. Piha‐Paul, et al.. (2023). Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer. 130(3). 400–409. 11 indexed citations

Stephen, Bettzy, Joud Hajjar, Shrutii Sarda, et al.. (2023). T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy. Journal for ImmunoTherapy of Cancer. 11(8). e007236–e007236. 9 indexed citations

10.

Ahmed, Jibran, Bettzy Stephen, Ece Kılıç, et al.. (2023). Abstract A121: Temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer. Molecular Cancer Therapeutics. 22(12_Supplement). A121–A121. 1 indexed citations

11.

Msaouel, Pavlos, et al.. (2023). A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma. Cancers. 15(15). 3806–3806. 10 indexed citations

12.

Nelson, Blessie Elizabeth, Bettzy Stephen, Jing Gong, et al.. (2022). Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience. Journal of Hematology. 11(3). 113–120. 5 indexed citations

13.

Güven, Deniz Can, et al.. (2022). The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials. Critical Reviews in Oncology/Hematology. 174. 103700–103700. 11 indexed citations

14.

Ferrarotto, Renata, Luana Guimarães de Sousa, Yun Qing, et al.. (2021). Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial. Advances in Therapy. 38(8). 4581–4591. 9 indexed citations

15.

Hahn, Andrew W., Jad Chahoud, Matthew T. Campbell, et al.. (2021). Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. Investigational New Drugs. 39(5). 1405–1410. 37 indexed citations

16.

Wheler, Jennifer J., Filip Jankú, Aung Naing, et al.. (2016). TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Molecular Cancer Therapeutics. 15(10). 2475–2485. 73 indexed citations

17.

Wheler, Jennifer J., Filip Jankú, Aung Naing, et al.. (2016). Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Research. 76(13). 3690–3701. 149 indexed citations

18.

Ganesan, Prasanth, Stacy L. Moulder, J. Jack Lee, et al.. (2014). Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents. Molecular Cancer Therapeutics. 13(12). 3175–3184. 29 indexed citations

19.

Wheler, Jennifer J., Apostolia M. Tsimberidou, David S. Hong, et al.. (2012). Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience. Clinical Cancer Research. 18(10). 2922–2929. 77 indexed citations

20.

Wheler, Jennifer J., Apostolia M. Tsimberidou, David S. Hong, et al.. (2012). Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Annals of Oncology. 23(8). 1963–1967. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact